Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Immunoconjugates
  • Maytansine
  • Receptor, ErbB-2

abstract

  • At the MTD of 3.6 mg/kg every 3 weeks, T-DM1 was associated with mild, reversible toxicity and substantial clinical activity in a heavily pretreated population. Phase II and III trials in patients with advanced HER2-positive breast cancer are under way.

publication date

  • June 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.26.2071

PubMed ID

  • 20421541

Additional Document Info

start page

  • 2698

end page

  • 704

volume

  • 28

number

  • 16